Validation of a method for the determination of the anticancer agent Combretastatin A1 phosphate (CA1P, OXi4503) in human plasma by HPLC with post-column photolysis and fluorescence detection

Validation of a method for the determination of the anticancer agent Combretastatin A1 phosphate (CA1P, OXi4503) in human plasma by HPLC with post-column photolysis and fluorescence detection

Show other versions (1)

Detalhes bibliográficos
Main Authors:	Stratford, M, Folkes, L
Formato:	Journal article
Publicado em:	2011

Registos relacionados

Validation of a method for the determination of the anticancer agent Combretastatin A1 phosphate (CA1P, OXi4503) in human plasma by HPLC with post-column photolysis and fluorescence detection.
Por: Stratford, MR, et al.
Publicado em: (2011)

Quantitative determination of the anticancer prodrug combretastatin A1 phosphate (OXi4503, CA1P), the active CA1 and its glucuronide metabolites in human urine and of CA1 in plasma by HPLC with mass spectrometric detection.
Por: Stratford, MR, et al.
Publicado em: (2012)

Enhanced fluorescence detection of cis-combretastatins by post-column photolysis.
Por: Stratford, MR
Publicado em: (2008)

A validated HPLC method with fluorescence detection for the glucuronides of Combretastatin A1 in human plasma, and studies on their cis-trans isomerisation
Por: Stratford, M, et al.
Publicado em: (2012)

A validated HPLC method with fluorescence detection for the glucuronides of Combretastatin A1 in human plasma, and studies on their cis-trans isomerisation.
Por: Stratford, MR, et al.
Publicado em: (2012)

Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors.
Por: Patterson, D, et al.
Publicado em: (2012)

Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results.
Por: Rustin, G, et al.
Publicado em: (2003)

A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer.
Por: Rustin, G, et al.
Publicado em: (2010)

Oxidative metabolism of combretastatin A-1 produces quinone intermediates with the potential to bind to nucleophiles and to enhance oxidative stress via free radicals.
Por: Folkes, L, et al.
Publicado em: (2007)

Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial
Por: Cummings, J, et al.
Publicado em: (2012)

Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial.
Por: Cummings, J, et al.
Publicado em: (2012)

Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer.
Por: Nathan, P, et al.
Publicado em: (2012)

Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo.
Por: Galbraith, S, et al.
Publicado em: (2001)

The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinically relevant doses.
Por: Prise, V, et al.
Publicado em: (2002)

A phase I study of combretastatin A4 phosphate (CA4P) and bevacizumab in subjects with advanced solid tumors
Por: Nathan, P, et al.
Publicado em: (2008)

Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate
Por: Jane Lunt, S, et al.
Publicado em: (2011)

Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate.
Por: Lunt, S, et al.
Publicado em: (2011)

Combretastatin A-4 phosphate (CA4P) carboplatin and paclitaxel in patients with platinum-resistant ovarian cancer: Final phase II trial results
Por: Zweifel, M, et al.
Publicado em: (2009)

Photolysis of 1-Octene and Molybdenum Hexacarbonyl in Tetrahydrofuran
Por: Card, Roger J., et al.
Publicado em: (1977)

The vascular targeting agent combretastatin A-4-phosphate induces neutrophil recruitment to endothelial cells in vitro.
Por: Brooks, A, et al.
Publicado em: (2003)

1-De-oxy-d-arabinitol.
Por: Jenkinson, S, et al.
Publicado em: (2008)

1-De-oxy-1-fluoro-l-galactitol.
Por: Jenkinson, S, et al.
Publicado em: (2010)

A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas.
Por: Meyer, T, et al.
Publicado em: (2009)

Synthesis and biological properties of bioreductively targeted nitrothienyl prodrugs of combretastatin A-4.
Por: Thomson, P, et al.
Publicado em: (2006)

Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.
Por: Zweifel, M, et al.
Publicado em: (2011)

1,5-Di-meth-oxy-naphthalene.
Por: Marfo-Owusu, E, et al.
Publicado em: (2013)

1-De-oxy-l-mannitol (6-de-oxy-l-mannitol or l-rhamnitol).
Por: Jenkinson, S, et al.
Publicado em: (2008)

1-Carb-oxy-methyl-3-octylimidazolium bromide
Por: Al-Mohammed, N.N., et al.
Publicado em: (2011)

1-De-oxy-d-galactitol (l-fucitol).
Por: Jenkinson, S, et al.
Publicado em: (2008)

Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability.
Por: Tozer, G, et al.
Publicado em: (2001)

A phase I study of the safety, tolerability and antitumor activity of escalating doses of combretastatin A4 phosphate (CA4P) given in combination with bevacizumab to subjects with advanced solid tumors
Por: Nathan, P, et al.
Publicado em: (2007)

Effect of Column Inlet and Outlet Geometry on Large-scale HPLC
Por: Tan, S.N., et al.
Publicado em: (2003)

1-[4-(Prop-2-en-1-yloxy)benzyl]-2-[4-(prop-2-en-1-yloxy)phenyl]-1H benzimidazole
Por: Hegde, Gurumurthy, et al.
Publicado em: (2012)

MEDI 570-Synthesis and photolysis studies of caged TRPV1 agonists and antagonists
Por: Conway, S, et al.
Publicado em: (2006)

Synthesis, photolysis studies and in vitro photorelease of caged TRPV1 agonists and antagonists.
Por: Ryssen, V, et al.
Publicado em: (2009)

Narrow bore HPLC columns with chemically bonded phase on porous glass /
Por: Lodkowski, R

1,1 `-{[1,4-Phenylenebis(methylene)]bis(oxy)bis(3,1-phenylene)}diethanon e
Por: Al-Mohammed, N.N., et al.
Publicado em: (2011)

1,1 `-{[1,4-Phenylenebis(methylene)]bis(oxy)bis(4,1-phenylene)}diethanon e
Por: Al-Mohammed, N.N., et al.
Publicado em: (2011)

N-Benzyl-1,3-dide-oxy-1,3-imino-l-xylitol.
Por: Jenkinson, S, et al.
Publicado em: (2011)

Nitric oxide synthase inhibition enhances the tumor vascular-damaging effects of combretastatin a-4 3-o-phosphate at clinically relevant doses.
Por: Tozer, G, et al.
Publicado em: (2009)